Ana Paula de Jesus Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana Paula de Jesus Santos has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Arne Krüger
Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
1 shared publication - Carsten Wrenger
Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
1 shared publication - Henning Ulrich
Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil
1 shared publication - Vanessa de Sá
Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo 05508-900-SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 28 June 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (7) , 622
Aptamer Applications in Emerging Viral Diseases
Aptamers are single-stranded DNA or RNA molecules which are submitted to a process denominated SELEX. SELEX uses reiterative screening of a random oligonucleotide library to identify high-affinity binders to a chosen target, which may be a peptide, protein, or entire cells or viral particles. Aptamers can rival antibodies in target recognition, and benefit from their non-proteic nature, ease of modification, increased stability, and pharmacokinetic properties. This turns them into ideal candidates for diagnostic as well as therapeutic applications. Here, we review the recent accomplishments in the development of aptamers targeting emerging viral diseases, with emphasis on recent findings of aptamers binding to coronaviruses. We focus on aptamer development for diagnosis, including biosensors, in addition to aptamer modifications for stabilization in body fluids and tissue penetration. Such aptamers are aimed at in vivo diagnosis and treatment, such as quantification of viral load and blocking host cell invasion, virus assembly, or replication, respectively. Although there are currently no in vivo applications of aptamers in combating viral diseases, such strategies are promising for therapy development in the future.
- 28 June 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (7) , 622
Open AccessAptamer Applications in Emerging Viral Diseases
Aptamers are single-stranded DNA or RNA molecules which are submitted to a process denominated SELEX. SELEX uses reiterative screening of a random oligonucleotide library to identify high-affinity binders to a chosen target, which may be a peptide, protein, or entire cells or viral particles. Aptamers can rival antibodies in target recognition, and benefit from their non-proteic nature, ease of modification, increased stability, and pharmacokinetic properties. This turns them into ideal candidates for diagnostic as well as therapeutic applications. Here, we review the recent accomplishments in the development of aptamers targeting emerging viral diseases, with emphasis on recent findings of aptamers binding to coronaviruses. We focus on aptamer development for diagnosis, including biosensors, in addition to aptamer modifications for stabilization in body fluids and tissue penetration. Such aptamers are aimed at in vivo diagnosis and treatment, such as quantification of viral load and blocking host cell invasion, virus assembly, or replication, respectively. Although there are currently no in vivo applications of aptamers in combating viral diseases, such strategies are promising for therapy development in the future.